Printer Friendly

ANGEION RECEIVES SEVEN PATENTS

 MINNEAPOLIS, April 13 /PRNewswire/ -- Angeion Corporation (NASDAQ: ANGN) has been notified by the United State Patent and Trademark Office that seven patents have been issued or allowed on its products to treat arrhythmia.
 Of the seven, one of the most significant concerns Angeion's process to identify the active site of cells which are responsible for conflicting electrical charges causing rapid heartbeats. This process is part of the nonsurgical procedure Angeion has been developing in conjunction with the development of its laser catheter ablation system. Angeion's mapping process simplifies the procedure and reduces the time required to identify the site of active conflicting cells in the heart.
 Also significant was the patent allowance concerning Angeion's smaller ICD. This patent provides coverage for the smaller size and more efficient application of energy.
 Minneapolis-based Angeion Corporation is developing products for treating various types of arrhythmias. The ICD and laser catheter ablation system are being developed to treat ventricular tachycardia, rapid heartbeats which affect approximately 1.4 million adults in the United States.
 -0- 4/13/93
 /CONTACT: Brenda Roth of Angeion Corporation, 612-550-9388/
 (ANGN ANI)


CO: Angeion Corporation ST: Minnesota IN: MTC SU:

DS -- MN004 -- 5150 04/13/93 10:39 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 13, 1993
Words:199
Previous Article:SAVVY INVESTING CAN CUT NEXT YEAR'S TAX BILL; VARIABLE ANNUITIES CAN SAVE ON TAXES WHILE BUILDING A RETIREMENT NEST EGG
Next Article:/C O R R E C T I O N -- LOJACK/
Topics:


Related Articles
ANGEION CORPORATION RAISES ADDITIONAL $2.1 MILLION
ANGEION REPORTS SECOND QUARTER FIGURES
ANGEION RECEIVES THREE MORE PATENTS
ANGEION RELEASES SECOND QUARTER FIGURES
Angeion and ELA Medical Collaboration Becomes Effective
Angeion Receives Suit From Cardiac Pacemakers, Inc.
Angeion Announces Three News Items: $5 Million Equity Investment; U.S. Clinical Studies of AngeFix Lead System; and European CE Mark to Market...
Angeion Transfers Certain Technology to ELA Medical In Exchange for Return of Common Stock and Warrants.
Angeion Holds and Adjourns Shareholder Meeting.
Angeion Shareholders Approve Two Transactions; Noteholders Fail to Vote.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters